Recent progress in the development of coumarin derivatives as potent anti-HIV agents

被引：493

作者：

Yu, DL ^{[1
]}

Suzuki, M ^{[1
]}

Xie, L ^{[1
]}

Morris-Natschke, SL ^{[1
]}

Lee, KH ^{[1
]}

机构：

[1] Univ N Carolina, Sch Pharm, Nat Prod Lab, Chapel Hill, NC 27599 USA

来源：

MEDICINAL RESEARCH REVIEWS | 2003年 / 23卷 / 03期

关键词：

anti-HIV coumarins; khellactone; DCK analogs; tetracyclic dipyranocoumarins; calanolides; inophyllums;

D O I：

10.1002/med.10034

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Numerous plant-derived compounds have been evaluated for inhibitory effects against HIV replication, and some coumarins have been found to inhibit different stages in the HIV replication cycle. This review article describes recent progress in the discovery, structure modification, and structure-activity relationship studies of potent anti-HIV coumarin derivatives. A dicamphanoyl-khellactone (DCK) analog, which was discovered and developed in our laboratory, and calanolide A are currently in preclinical studies and clinical trials, respectively. (C) 2003 Wiley Periodicals, Inc. Med Res Rev, 23, No. 3, 322-345, 2003.

引用

页码：322 / 345

页数：24

共 74 条

[1] The amphiphilic properties of novenamines determine their activity as inhibitors of HIV-1 RNase H [J].

Althaus, IW ;

Franks, KM ;

Langley, KB ;

Kezdy, FJ ;

Peterson, T ;

Buxser, SE ;

Decker, DE ;

Dolak, LA ;

Ulrich, RG ;

Reusser, F .

EXPERIENTIA, 1996, 52 (04) :329-335

[2] ISOLATION OF A T-LYMPHOTROPIC RETROVIRUS FROM A PATIENT AT RISK FOR ACQUIRED IMMUNE-DEFICIENCY SYNDROME (AIDS) [J].

BARRESINOUSSI, F ;

CHERMANN, JC ;

REY, F ;

NUGEYRE, MT ;

CHAMARET, S ;

GRUEST, J ;

DAUGUET, C ;

AXLERBLIN, C ;

VEZINETBRUN, F ;

ROUZIOUX, C ;

ROZENBAUM, W ;

MONTAGNIER, L .

SCIENCE, 1983, 220 (4599) :868-871

[3] Unique anti-human immunodeficiency virus activities of the nonnucleoside reverse transcriptase inhibitors calanolide A, costatolide, and dihydrocostatolide [J].

Buckheit, RW ;

White, EL ;

Fliakas-Boltz, V ;

Russell, J ;

Stup, TL ;

Kinjerski, TL ;

Osterling, MC ;

Weigand, A ;

Bader, JP .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (08) :1827-1834

[4] Anti-HIV-1 activity of calanolides used in combination with other mechanistically diverse inhibitors of HIV-1 replication [J].

Buckheit, RW ;

Russell, JD ;

Xu, ZQ ;

Flavin, M .

ANTIVIRAL CHEMISTRY & CHEMOTHERAPY, 2000, 11 (05) :321-327

[5] In vitro combination of PNU-140690, a human immunodeficiency virus type 1 protease inhibitor, with ritonavir against ritonavir-sensitive and -resistant clinical isolates [J].

Chong, KT ;

Pagano, PJ .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (11) :2367-2373

[6] Safety and pharmacokinetics of single doses of (+)-calanolide A, a novel, naturally occurring nonnucleoside reverse transcriptase inhibitor, in healthy, human immunodeficiency virus-negative human subjects [J].

Creagh, T ;

Ruckle, JL ;

Tolbert, DT ;

Giltner, J ;

Eiznhamer, DA ;

Dutta, B ;

Flavin, MT ;

Xu, ZQ .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (05) :1379-1386

[7]

Currens MJ, 1996, J PHARMACOL EXP THER, V279, P652

[8]

Currens MJ, 1996, J PHARMACOL EXP THER, V279, P645

[9] HIV-1 integrase:: the next target for AIDS therapy? [J].

d'Angelo, J ;

Mouscadet, JF ;

Desmaële, D ;

Zouhiri, F ;

Leh, H .

PATHOLOGIE BIOLOGIE, 2001, 49 (03) :237-246

[10]

De Clercq E, 2000, MED RES REV, V20, P323, DOI 10.1002/1098-1128(200009)20:5<323::AID-MED1>3.0.CO

← 1 2 3 4 5 6 7 8 →